Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TOVX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Insufficient Stockholder Participation to Achieve Quorum (new) — Low shareholder engagement may signal weak retail support or concerns about the proposed dilution.
Theriva Biologics fails to achieve quorum for vote on 16.2M share warrant dilution
Filed April 9, 2026 · Period ending April 9, 2026 · ~1 min read
Key Changes
-
high
Special stockholder meeting on April 9 failed to reach quorum, preventing vote on issuing 16.2 million shares to warrant holders from October 2025 financing deal.
Item 8.01 verify on EDGAR → -
medium
Company contractually obligated to call new stockholder meetings every 60 days until approval obtained or warrants expire, creating ongoing uncertainty.
Item 8.01 verify on EDGAR → -
high
Warrant exercise approval required under October 2025 inducement agreement with institutional investors for up to 16,184,560 common shares.
Item 8.01 verify on EDGAR →
Summary
Theriva Biologics attempted to hold a special stockholder meeting on April 9, 2026, but failed to achieve the minimum quorum needed to conduct business. The meeting's purpose was to approve issuing up to 16.2 million shares of common stock upon exercise of warrants held by institutional investors—a commitment the company made in an October 2025 financing agreement.
Without shareholder approval, these warrants cannot be exercised, potentially creating friction with the institutional investors who provided capital. The failed quorum matters because it signals either low shareholder engagement or possible resistance to the dilution.
The company is now contractually required to call another meeting within 60 days and continue doing so every 60 days until approval is obtained or the warrants expire. This creates ongoing uncertainty about when and whether the dilution will occur. Retail investors should watch for the next meeting announcement and consider whether the 16.2 million share dilution (which could represent significant percentage dilution depending on current share count) aligns with their investment thesis. The company's ability to secure quorum at the next attempt will be a key indicator of shareholder sentiment.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Special stockholder meeting failed to achieve quorum; company must reschedule to seek approval for warrant exercise shares under inducement agreement.
Added in current filing · verify on EDGAR →
On April 9, 2026, Theriva Biologics, Inc. (the “Company”) called to order its Special Meeting of Stockholders (the “Special Meeting”). At that time, there were not present or represented by proxy a sufficient number of shares of the Company’s common stock to constitute a quorum. As a result, the Company was not able to convene the Special Meeting.
The company attempted to hold a Special Meeting of Stockholders on April 9, 2026, but failed to achieve the minimum number of shares present or represented by proxy needed to conduct business. This means the meeting could not proceed and no votes could be taken on the proposals.
Added in current filing · verify on EDGAR →
Because the Company was not able to convene the Special Meeting, unless waived by the investors, the Company will be required under the Inducement Agreement to continue to call an additional meeting of stockholders every 60 days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the New Warrants are no longer outstanding.
Due to the failed quorum, the company must now call a new stockholder meeting every 60 days until either approval is obtained or the warrants expire, unless the institutional investors waive this requirement. This creates an ongoing administrative burden and uncertainty about when the warrant exercise approval will be secured.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify